14.08.2007

Nabriva Therapeutics announced today commencement of a clinical phase I program for its topical pleuromutilin antibiotic BC-7013

27.06.2007

Nabriva Therapeutics has appointed Dr. Robert Moellering to its Supervisory Board.

05.06.2007

Dr. John Goka has just joined the Nabriva management team as Chief Medical Officer.

31.01.2006

Launch of Nabriva GmbH, specialist antibiotic research company / Spin off from Sandoz GmbH / €42m financing round led by Nomura Phase4 Ventures

Print page